SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...
Medscape4d
Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDE
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
ConsumerAffairs3d
Oral Semaglutide (GLP-1) may reduce heart attack, stroke risk in diabetes patients
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...
Yahoo Finance3d
SCORE analysis of semaglutide 2.4 mg demonstrated risk reduction in cardiovascular events in a real-world setting
risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients in the U.S. with obesity or overweight and ...
FOX59 News4d
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...